{"id":3363,"date":"2026-06-01T08:00:28","date_gmt":"2026-06-01T15:00:28","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3363"},"modified":"2026-06-01T08:00:30","modified_gmt":"2026-06-01T15:00:30","slug":"chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/","title":{"rendered":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">On May 29, the official website of the National Medical Products Administration (NMPA) announced that two imported innovative drugs have obtained marketing approval in China. The first is <strong>Naldemedine Tosylate (brand name: Symproic\u00ae)<\/strong>, a new therapeutic agent for opioid-induced constipation (OIC), exclusively introduced by Chia Tai Tianqing. The second is <strong>Fosnetupitant and Palonosetron Concentrate for Solution for Injection (AKYNZEO\u00ae, NEPA)<\/strong>, a fixed-combination antiemetic for chemotherapy-induced nausea and vomiting imported by FOSUN PHARMA and Helsinn Group. Covering two key areas including cancer supportive care and supportive treatment for pain management, the two drugs further diversify clinical treatment options across the country.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>I. New Addition to Chia Tai Tianqing\u2019s Product Portfolio!Naldemedine Approved to Address Opioid-Induced Constipation<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Developed by Shionogi and commercially launched in China by Chia Tai Tianqing, Naldemedine has officially been approved for marketing by the NMPA (Acceptance No.: JXHS2500060). It is specifically indicated for the treatment of opioid-induced constipation (OIC), filling an unmet need for precision clinical treatment in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to data from Moinfo Pharma Database, Naldemedine is the world\u2019s first orally administered selective peripheral mu-opioid receptor antagonist with a precise and unique mechanism of action. The drug specifically blocks the binding between opioids and mu-receptors in the intestinal tract, fundamentally reversing the pathological effects of opioids that inhibit intestinal peristalsis and reduce intestinal fluid secretion. It rapidly restores normal intestinal physiological rhythms and effectively relieves OIC symptoms, without compromising the central analgesic effect of opioids, thus balancing therapeutic efficacy and medication safety. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This innovative drug has been approved for marketing in multiple countries and regions including the United States, the European Union, Japan and Hong Kong of China. Its rollout in China has progressed steadily: it was introduced to Hainan Lecheng Medical Pilot Zone as a clinically urgently needed drug in 2022. In April 2026, it was first available at designated medical institutions in the Guangdong-Hong Kong-Macao Greater Bay Area under the Guangdong <em>Hong Kong and Macao Medicine and Medical Device Access Policy<\/em>. The latest NMPA approval enables its legal nationwide launch in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In terms of commercialization, in January 2025, Chia Tai Tianqing Pharmaceutical Group, an affiliate of China National Biotec Group, signed an exclusive marketing agreement with Shionogi Group, securing the exclusive marketing rights of Naldemedine across mainland China. Since the start of this year, as a clinically urgently needed drug, Naldemedine has been accessible in Hainan via the Boao Lecheng International Medical Tourism Pilot Zone policy and in the Greater Bay Area under the <em>Hong Kong and Macao Medicine and Medical Device Access Policy<\/em>. Following its nationwide approval, Chia Tai Tianqing will leverage its robust commercial capabilities to bring this globally innovative therapy to more patients with OIC and help improve the standard of cancer supportive care in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>II. Introduced by FOSUN PHARMA: Globally Approved Dual-Target Antiemetic Launches in China for Full-cycle Control of Chemotherapy-Induced Vomiting<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The newly approved Fosnetupitant and Palonosetron Concentrate for Solution for Injection (AKYNZEO\u00ae, NEPA) is a Class 5.1 imported fixed-combination innovative drug co-introduced by FOSUN PHARMA and Helsinn Group. It is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), offering a brand-new long-acting therapeutic solution for antiemetic treatment in China\u2019s clinical practice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As an innovative dual-mechanism fixed-combination preparation, this drug consists of 235 mg fosnetupitant and 0.25 mg palonosetron. Fosnetupitant acts as an NK1 receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist. The synergistic effect of the dual targets provides comprehensive control over both acute and delayed chemotherapy-induced vomiting, markedly improving the overall control rate of refractory CINV. Meanwhile, it simplifies combined medication regimens in clinical settings and enhances medical service efficiency. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A well-established global innovative product, it first obtained marketing approval in the United States in April 2018 for use in combination with dexamethasone to prevent acute and delayed nausea and vomiting induced by highly emetogenic chemotherapy in adults. It subsequently secured marketing authorization from the European Union in December 2021, with its clinical efficacy and safety validated in numerous regions worldwide.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Back in October 2021, FOSUN PHARMA entered into an in-depth strategic cooperation with Helsinn Group. Fosun Pharma AG, its wholly-owned subsidiary based in Switzerland, obtained the exclusive distribution, promotion and sales rights for intravenous formulations of Aloxi\u00ae, AKYNZEO\u00ae and NEPA, as well as the pipeline drug Anamorelin in mainland China, Hong Kong and Macao. The successful launch of NEPA in China marks a major milestone of the partnership.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>III. Conclusion<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The launch of the two innovative drugs greatly optimizes the full-cycle management system for cancer treatment in China and delivers more efficient and high-quality innovative therapeutic options for clinical use. Meanwhile, it reflects the prevailing trend of domestic pharmaceutical enterprises expanding product pipelines by conducting international collaborations and rapidly introducing high-quality innovative medicines. These efforts continuously improve the accessibility of innovative medications for patients in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Symproic(Naldemedine Tosylate) or \u00a0AKYNZEO(NEPA) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 29, the official website of the National Medical Products Administration (NMPA) announced that two imported innovative drugs have obtained marketing approval in China. The first is Naldemedine Tosylate (brand name: Symproic\u00ae), a new therapeutic agent for opioid-induced constipation (OIC), exclusively introduced by Chia Tai Tianqing. The second is Fosnetupitant and Palonosetron Concentrate for [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2775,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3363","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China<\/title>\n<meta name=\"description\" content=\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing\uff1asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing\uff1asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T15:00:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T15:00:30+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"344\" \/>\n\t<meta property=\"og:image:height\" content=\"146\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China\",\"datePublished\":\"2026-06-01T15:00:28+00:00\",\"dateModified\":\"2026-06-01T15:00:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/\"},\"wordCount\":844,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/chiatai-tianqing.jpg\",\"articleSection\":[\"Drug news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/\",\"name\":\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/chiatai-tianqing.jpg\",\"datePublished\":\"2026-06-01T15:00:28+00:00\",\"dateModified\":\"2026-06-01T15:00:30+00:00\",\"description\":\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/chiatai-tianqing.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/chiatai-tianqing.jpg\",\"width\":344,\"height\":146,\"caption\":\"Symproic\u00aeNaldemedine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/drug-news\\\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","description":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing\uff1asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/","og_locale":"en_US","og_type":"article","og_title":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","og_description":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing\uff1asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-01T15:00:28+00:00","article_modified_time":"2026-06-01T15:00:30+00:00","og_image":[{"width":344,"height":146,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China","datePublished":"2026-06-01T15:00:28+00:00","dateModified":"2026-06-01T15:00:30+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/"},"wordCount":844,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg","articleSection":["Drug news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/","url":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/","name":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg","datePublished":"2026-06-01T15:00:28+00:00","dateModified":"2026-06-01T15:00:30+00:00","description":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/chiatai-tianqing.jpg","width":344,"height":146,"caption":"Symproic\u00aeNaldemedine"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/drug-news\/chia-tai-tianqing%ef%bc%9asymproicnaldemedine-tosylate-and-fosun-pharmaakynzeonepa-have-been-approved-for-marketing-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Chia Tai Tianqing\uff1aSymproic\u00aeNaldemedine Tosylate and FOSUN PHARMA:AKYNZEO\u00aeNEPA have been approved for marketing in China"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3363"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3363\/revisions"}],"predecessor-version":[{"id":3386,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3363\/revisions\/3386"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/2775"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}